Loading…
Drug induced liver injury: an update
Drug induced liver injury (DILI) is a relatively rare hepatic condition in response to the use of medications, illegal drugs, herbal products or dietary supplements. It occurs in susceptible individuals through a combination of genetic and environmental risk factors believed to modify drug metabolis...
Saved in:
Published in: | Archives of toxicology 2020-10, Vol.94 (10), p.3381-3407 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c352t-3ab5c5c78d325be57f9c9b0a14ec7338da01cfbacc68ba671870768bd1ca8e603 |
---|---|
cites | cdi_FETCH-LOGICAL-c352t-3ab5c5c78d325be57f9c9b0a14ec7338da01cfbacc68ba671870768bd1ca8e603 |
container_end_page | 3407 |
container_issue | 10 |
container_start_page | 3381 |
container_title | Archives of toxicology |
container_volume | 94 |
creator | Garcia-Cortes, Miren Robles-Diaz, Mercedes Stephens, Camilla Ortega-Alonso, Aida Lucena, M. Isabel Andrade, Raúl J. |
description | Drug induced liver injury (DILI) is a relatively rare hepatic condition in response to the use of medications, illegal drugs, herbal products or dietary supplements. It occurs in susceptible individuals through a combination of genetic and environmental risk factors believed to modify drug metabolism and/or excretion leading to a cascade of cellular events, including oxidative stress formation, apoptosis/necrosis, haptenization, immune response activation and a failure to adapt. The resultant liver damage can present with an array of phenotypes, which mimic almost every other liver disorder, and varies in severity from asymptomatic elevation of liver tests to fulminant hepatic failure. Despite recent research efforts specific biomarkers are not still available for routine use in clinical practice, which makes the diagnosis of DILI uncertain and relying on a high degree of awareness of this condition and the exclusion of other causes of liver disease. Diagnostic scales such as the CIOMS/RUCAM can support the causality assessment of a DILI suspicion, but need refinement as some criteria are not evidence-based. Prospective collection of well-vetted DILI cases in established DILI registries has allowed the identification and validation of a number of clinical variables, and to predict a more severe DILI outcome. DILI is also in need of properly designed clinical trials to evaluate the efficacy of new DILI treatments as well as older drugs such as ursodeoxycholic acid traditionally used to ameliorate cholestasis or corticosteroids now widely tried in the oncology field to manage the emergent type of hepatotoxicity related to immune checkpoint inhibitors. |
doi_str_mv | 10.1007/s00204-020-02885-1 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2694723735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2694723735</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-3ab5c5c78d325be57f9c9b0a14ec7338da01cfbacc68ba671870768bd1ca8e603</originalsourceid><addsrcrecordid>eNp9UE1LxDAQDaJgXf0Dngp6jU4yTZN6k_UTFrzoOaRJurSsbU1aYf-90QrePMybGXgf8Ag5Z3DFAOR1BOBQ0ARplBKUHZCMFcgpSFSHJAMsgApZsmNyEmMHwLiqMCOXd2He5m3vZutdvms_fUhfN4f9TW76fB6dmfwpOWrMLvqz370ibw_3r-snunl5fF7fbqhFwSeKphZWWKkcclF7IZvKVjUYVngrEZUzwGxTG2tLVZtSMiVBptMxa5QvAVfkYvEdw_Ax-zjpbphDnyI1L6tCcpQoEosvLBuGGINv9BjadxP2moH-bkMvbegE-qcNzZIIF1FM5H7rw5_1P6ovPRxgsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2694723735</pqid></control><display><type>article</type><title>Drug induced liver injury: an update</title><source>Springer Nature</source><creator>Garcia-Cortes, Miren ; Robles-Diaz, Mercedes ; Stephens, Camilla ; Ortega-Alonso, Aida ; Lucena, M. Isabel ; Andrade, Raúl J.</creator><creatorcontrib>Garcia-Cortes, Miren ; Robles-Diaz, Mercedes ; Stephens, Camilla ; Ortega-Alonso, Aida ; Lucena, M. Isabel ; Andrade, Raúl J.</creatorcontrib><description>Drug induced liver injury (DILI) is a relatively rare hepatic condition in response to the use of medications, illegal drugs, herbal products or dietary supplements. It occurs in susceptible individuals through a combination of genetic and environmental risk factors believed to modify drug metabolism and/or excretion leading to a cascade of cellular events, including oxidative stress formation, apoptosis/necrosis, haptenization, immune response activation and a failure to adapt. The resultant liver damage can present with an array of phenotypes, which mimic almost every other liver disorder, and varies in severity from asymptomatic elevation of liver tests to fulminant hepatic failure. Despite recent research efforts specific biomarkers are not still available for routine use in clinical practice, which makes the diagnosis of DILI uncertain and relying on a high degree of awareness of this condition and the exclusion of other causes of liver disease. Diagnostic scales such as the CIOMS/RUCAM can support the causality assessment of a DILI suspicion, but need refinement as some criteria are not evidence-based. Prospective collection of well-vetted DILI cases in established DILI registries has allowed the identification and validation of a number of clinical variables, and to predict a more severe DILI outcome. DILI is also in need of properly designed clinical trials to evaluate the efficacy of new DILI treatments as well as older drugs such as ursodeoxycholic acid traditionally used to ameliorate cholestasis or corticosteroids now widely tried in the oncology field to manage the emergent type of hepatotoxicity related to immune checkpoint inhibitors.</description><identifier>ISSN: 0340-5761</identifier><identifier>EISSN: 1432-0738</identifier><identifier>DOI: 10.1007/s00204-020-02885-1</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Apoptosis ; Biomarkers ; Biomedical and Life Sciences ; Biomedicine ; Causality ; Cholestasis ; Clinical trials ; Corticoids ; Corticosteroids ; Diet ; Dietary supplements ; Drug metabolism ; Drugs ; Environmental Health ; Environmental risk ; Hepatotoxicity ; Immune checkpoint inhibitors ; Immune response ; Immune system ; Immunosuppressive agents ; Liver ; Liver diseases ; Necrosis ; Occupational Medicine/Industrial Medicine ; Oxidative stress ; Pharmacology/Toxicology ; Phenotypes ; Review Article ; Risk analysis ; Risk factors ; Ursodeoxycholic acid</subject><ispartof>Archives of toxicology, 2020-10, Vol.94 (10), p.3381-3407</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-3ab5c5c78d325be57f9c9b0a14ec7338da01cfbacc68ba671870768bd1ca8e603</citedby><cites>FETCH-LOGICAL-c352t-3ab5c5c78d325be57f9c9b0a14ec7338da01cfbacc68ba671870768bd1ca8e603</cites><orcidid>0000-0001-9586-4896</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Garcia-Cortes, Miren</creatorcontrib><creatorcontrib>Robles-Diaz, Mercedes</creatorcontrib><creatorcontrib>Stephens, Camilla</creatorcontrib><creatorcontrib>Ortega-Alonso, Aida</creatorcontrib><creatorcontrib>Lucena, M. Isabel</creatorcontrib><creatorcontrib>Andrade, Raúl J.</creatorcontrib><title>Drug induced liver injury: an update</title><title>Archives of toxicology</title><addtitle>Arch Toxicol</addtitle><description>Drug induced liver injury (DILI) is a relatively rare hepatic condition in response to the use of medications, illegal drugs, herbal products or dietary supplements. It occurs in susceptible individuals through a combination of genetic and environmental risk factors believed to modify drug metabolism and/or excretion leading to a cascade of cellular events, including oxidative stress formation, apoptosis/necrosis, haptenization, immune response activation and a failure to adapt. The resultant liver damage can present with an array of phenotypes, which mimic almost every other liver disorder, and varies in severity from asymptomatic elevation of liver tests to fulminant hepatic failure. Despite recent research efforts specific biomarkers are not still available for routine use in clinical practice, which makes the diagnosis of DILI uncertain and relying on a high degree of awareness of this condition and the exclusion of other causes of liver disease. Diagnostic scales such as the CIOMS/RUCAM can support the causality assessment of a DILI suspicion, but need refinement as some criteria are not evidence-based. Prospective collection of well-vetted DILI cases in established DILI registries has allowed the identification and validation of a number of clinical variables, and to predict a more severe DILI outcome. DILI is also in need of properly designed clinical trials to evaluate the efficacy of new DILI treatments as well as older drugs such as ursodeoxycholic acid traditionally used to ameliorate cholestasis or corticosteroids now widely tried in the oncology field to manage the emergent type of hepatotoxicity related to immune checkpoint inhibitors.</description><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Causality</subject><subject>Cholestasis</subject><subject>Clinical trials</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>Diet</subject><subject>Dietary supplements</subject><subject>Drug metabolism</subject><subject>Drugs</subject><subject>Environmental Health</subject><subject>Environmental risk</subject><subject>Hepatotoxicity</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunosuppressive agents</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Necrosis</subject><subject>Occupational Medicine/Industrial Medicine</subject><subject>Oxidative stress</subject><subject>Pharmacology/Toxicology</subject><subject>Phenotypes</subject><subject>Review Article</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Ursodeoxycholic acid</subject><issn>0340-5761</issn><issn>1432-0738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9UE1LxDAQDaJgXf0Dngp6jU4yTZN6k_UTFrzoOaRJurSsbU1aYf-90QrePMybGXgf8Ag5Z3DFAOR1BOBQ0ARplBKUHZCMFcgpSFSHJAMsgApZsmNyEmMHwLiqMCOXd2He5m3vZutdvms_fUhfN4f9TW76fB6dmfwpOWrMLvqz370ibw_3r-snunl5fF7fbqhFwSeKphZWWKkcclF7IZvKVjUYVngrEZUzwGxTG2tLVZtSMiVBptMxa5QvAVfkYvEdw_Ax-zjpbphDnyI1L6tCcpQoEosvLBuGGINv9BjadxP2moH-bkMvbegE-qcNzZIIF1FM5H7rw5_1P6ovPRxgsQ</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Garcia-Cortes, Miren</creator><creator>Robles-Diaz, Mercedes</creator><creator>Stephens, Camilla</creator><creator>Ortega-Alonso, Aida</creator><creator>Lucena, M. Isabel</creator><creator>Andrade, Raúl J.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>Q9U</scope><orcidid>https://orcid.org/0000-0001-9586-4896</orcidid></search><sort><creationdate>20201001</creationdate><title>Drug induced liver injury: an update</title><author>Garcia-Cortes, Miren ; Robles-Diaz, Mercedes ; Stephens, Camilla ; Ortega-Alonso, Aida ; Lucena, M. Isabel ; Andrade, Raúl J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-3ab5c5c78d325be57f9c9b0a14ec7338da01cfbacc68ba671870768bd1ca8e603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Causality</topic><topic>Cholestasis</topic><topic>Clinical trials</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>Diet</topic><topic>Dietary supplements</topic><topic>Drug metabolism</topic><topic>Drugs</topic><topic>Environmental Health</topic><topic>Environmental risk</topic><topic>Hepatotoxicity</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunosuppressive agents</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Necrosis</topic><topic>Occupational Medicine/Industrial Medicine</topic><topic>Oxidative stress</topic><topic>Pharmacology/Toxicology</topic><topic>Phenotypes</topic><topic>Review Article</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Ursodeoxycholic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garcia-Cortes, Miren</creatorcontrib><creatorcontrib>Robles-Diaz, Mercedes</creatorcontrib><creatorcontrib>Stephens, Camilla</creatorcontrib><creatorcontrib>Ortega-Alonso, Aida</creatorcontrib><creatorcontrib>Lucena, M. Isabel</creatorcontrib><creatorcontrib>Andrade, Raúl J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><jtitle>Archives of toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garcia-Cortes, Miren</au><au>Robles-Diaz, Mercedes</au><au>Stephens, Camilla</au><au>Ortega-Alonso, Aida</au><au>Lucena, M. Isabel</au><au>Andrade, Raúl J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug induced liver injury: an update</atitle><jtitle>Archives of toxicology</jtitle><stitle>Arch Toxicol</stitle><date>2020-10-01</date><risdate>2020</risdate><volume>94</volume><issue>10</issue><spage>3381</spage><epage>3407</epage><pages>3381-3407</pages><issn>0340-5761</issn><eissn>1432-0738</eissn><abstract>Drug induced liver injury (DILI) is a relatively rare hepatic condition in response to the use of medications, illegal drugs, herbal products or dietary supplements. It occurs in susceptible individuals through a combination of genetic and environmental risk factors believed to modify drug metabolism and/or excretion leading to a cascade of cellular events, including oxidative stress formation, apoptosis/necrosis, haptenization, immune response activation and a failure to adapt. The resultant liver damage can present with an array of phenotypes, which mimic almost every other liver disorder, and varies in severity from asymptomatic elevation of liver tests to fulminant hepatic failure. Despite recent research efforts specific biomarkers are not still available for routine use in clinical practice, which makes the diagnosis of DILI uncertain and relying on a high degree of awareness of this condition and the exclusion of other causes of liver disease. Diagnostic scales such as the CIOMS/RUCAM can support the causality assessment of a DILI suspicion, but need refinement as some criteria are not evidence-based. Prospective collection of well-vetted DILI cases in established DILI registries has allowed the identification and validation of a number of clinical variables, and to predict a more severe DILI outcome. DILI is also in need of properly designed clinical trials to evaluate the efficacy of new DILI treatments as well as older drugs such as ursodeoxycholic acid traditionally used to ameliorate cholestasis or corticosteroids now widely tried in the oncology field to manage the emergent type of hepatotoxicity related to immune checkpoint inhibitors.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00204-020-02885-1</doi><tpages>27</tpages><orcidid>https://orcid.org/0000-0001-9586-4896</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-5761 |
ispartof | Archives of toxicology, 2020-10, Vol.94 (10), p.3381-3407 |
issn | 0340-5761 1432-0738 |
language | eng |
recordid | cdi_proquest_journals_2694723735 |
source | Springer Nature |
subjects | Apoptosis Biomarkers Biomedical and Life Sciences Biomedicine Causality Cholestasis Clinical trials Corticoids Corticosteroids Diet Dietary supplements Drug metabolism Drugs Environmental Health Environmental risk Hepatotoxicity Immune checkpoint inhibitors Immune response Immune system Immunosuppressive agents Liver Liver diseases Necrosis Occupational Medicine/Industrial Medicine Oxidative stress Pharmacology/Toxicology Phenotypes Review Article Risk analysis Risk factors Ursodeoxycholic acid |
title | Drug induced liver injury: an update |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A24%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20induced%20liver%20injury:%20an%20update&rft.jtitle=Archives%20of%20toxicology&rft.au=Garcia-Cortes,%20Miren&rft.date=2020-10-01&rft.volume=94&rft.issue=10&rft.spage=3381&rft.epage=3407&rft.pages=3381-3407&rft.issn=0340-5761&rft.eissn=1432-0738&rft_id=info:doi/10.1007/s00204-020-02885-1&rft_dat=%3Cproquest_cross%3E2694723735%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c352t-3ab5c5c78d325be57f9c9b0a14ec7338da01cfbacc68ba671870768bd1ca8e603%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2694723735&rft_id=info:pmid/&rfr_iscdi=true |